Found: 4
Select item for more details and to access through your institution.
Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.
- Published in:
- Pharmaceutics, 2019, v. 11, n. 4, p. 152, doi. 10.3390/pharmaceutics11040152
- By:
- Publication type:
- Article
Influence of lithium cations on prolyl peptide bonds.
- Published in:
- Journal of Peptide Science, 2012, v. 18, n. 6, p. 400, doi. 10.1002/psc.2410
- By:
- Publication type:
- Article
Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.
- Published in:
- Cancers, 2020, v. 12, n. 12, p. 3683, doi. 10.3390/cancers12123683
- By:
- Publication type:
- Article
ATIM-13. ASUNERCEPT PLUS RADIOTHERAPY IN RELAPSED GLIOBLASTOMA. UPDATE ON FIVE YEARS OVERALL SURVIVAL OF STUDY NCT01071837 AND DEVELOPMENT OF A POPULATION-PK - TUMOR GROWTH INHIBITION - SURVIVAL MODEL.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi3, doi. 10.1093/neuonc/noy148.008
- By:
- Publication type:
- Article